AxoGen (NASDAQ:AXGN) CFO Sells $442,286.32 in Stock

AxoGen, Inc. (NASDAQ:AXGN) CFO Lindsey Marie Hartley sold 14,812 shares of AxoGen stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $29.86, for a total transaction of $442,286.32. Following the completion of the sale, the chief financial officer owned 31,376 shares of the company’s stock, valued at $936,887.36. This trade represents a 32.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Lindsey Marie Hartley also recently made the following trade(s):

• On Monday, December 8th, Lindsey Marie Hartley sold 14,387 shares of AxoGen stock. The stock was sold at an average price of $31.56, for a total value of $454,053.72.

AxoGen Trading Up 0.9%

AXGN opened at $31.98 on Friday. The company has a quick ratio of 2.64, a current ratio of 4.09 and a debt-to-equity ratio of 0.54. The firm has a market cap of $1.47 billion, a P/E ratio of -639.60 and a beta of 1.06. AxoGen, Inc. has a 52 week low of $9.22 and a 52 week high of $34.24. The business has a fifty day simple moving average of $24.71 and a 200-day simple moving average of $17.59.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. The firm had revenue of $60.08 million for the quarter, compared to analyst estimates of $56.90 million. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%. On average, equities analysts expect that AxoGen, Inc. will post -0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Mizuho assumed coverage on AxoGen in a report on Monday, December 1st. They set an “outperform” rating and a $40.00 price target on the stock. Citizens Jmp upped their target price on shares of AxoGen from $26.00 to $34.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th. JMP Securities set a $34.00 target price on shares of AxoGen in a report on Thursday, October 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of AxoGen in a report on Monday. Finally, Canaccord Genuity Group increased their price objective on shares of AxoGen from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.56.

Institutional Investors Weigh In On AxoGen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Future Financial Wealth Managment LLC purchased a new stake in AxoGen in the third quarter valued at $27,000. Aquatic Capital Management LLC lifted its holdings in shares of AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of AxoGen in the 3rd quarter valued at about $43,000. FNY Investment Advisers LLC acquired a new stake in shares of AxoGen in the 3rd quarter valued at about $64,000. Finally, AdvisorNet Financial Inc grew its stake in AxoGen by 500.0% during the 3rd quarter. AdvisorNet Financial Inc now owns 4,800 shares of the medical equipment provider’s stock worth $86,000 after buying an additional 4,000 shares during the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.